Figure 3
From: CRTAC1 identified as a promising diagnosis and prognostic biomarker in lung adenocarcinoma
Analysis of the differential expression of CRTAC1 and its prognostic and diagnostic value in LUAD. (A) CRTAC1 mRNA expression was significantly reduced in the majority of tumors compared to normal tissues. (B,C) CRTAC1 mRNA expression was significantly lower in LUAD tissues as compared to normal tissues based on TCGA and GSE31210. (D,E) CRTAC1 protein expression was significantly lower in LUAD tissues compared to normal tissues based on Human Protein Atlas. (F) Volcano plot of DEGs between the low and high CRTAC1 expression groups. The red points represent upregulated genes screened on the basis of p.adj < 0.05 and |log2FC|> 1. The blue points represent downregulation of the expression of genes screened on the basis of p.adj < 0.05 and |log2FC|> 1. The gray points represent genes with no significant difference. (G) GSEA showed five pathways enriched in the low CRTAC1 groups. (H) The ROC curves demonstrated that CRTAC1 exhibited superior predictive efficacy (AUC = 0.972). (I,J) Kaplan‐Meier survival curves of LUAD patients from TCGA and GSE31210 showed the high CRTAC1 mRNA expression group exhibited a more favorable prognosis compared to the low expression group. (K) A nomogram integrated CRTAC1 expression and clinicopathological characteristics for predicting the probability of 1-, 3- and 5-year OS. (L) Calibration curve analysis results suggested that the predicted survival probabilities closely approximated the ideal line for 1-, 3-, and 5-year overall survival. ****p < 0.0001, ***p < 0.001, **p < 0.01, *p < 0.05, ns, no significance. DEGs, differentially expressed genes; FC, fold change; GSEA, Gene Set Enrichment Analysis; ROC, receiver operating characteristic curves; AUC, area under the ROC curve; OS, overall survival.
